Unveiling 7 Analyst Insights On Glaukos
Portfolio Pulse from Benzinga Insights
Analysts have provided varied ratings for Glaukos (NYSE:GKOS) over the last quarter, with recent updates showing an average 12-month price target of $80.86, up from the previous $75.25. The highest target is $91.00 and the lowest is $65.00. Analyst actions include ratings from 'Overweight' to 'Neutral' and price target adjustments. Glaukos is an ophthalmic medical technology company with products like iStent. Despite positive revenue growth, the company's market capitalization, net margin, ROE, and ROA are below industry averages, although it has a sound debt-to-equity ratio.
December 21, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have mixed views on Glaukos, with recent price target updates suggesting a bullish sentiment. The company's financials show positive revenue growth but below-average profitability and market cap.
The increase in the average price target to $80.86 reflects a positive sentiment among analysts, which could lead to a short-term bullish impact on GKOS stock. However, the company's financial challenges, such as lower profitability and market cap, may temper investor enthusiasm, hence the importance score is not at the maximum.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100